Review Of GROWTH HORMONE-RELEASING PEPTIDE-2
06April 6, 2023
By mimicking the action of ghrelin, GHRP-2 can effectively enhance growth hormone release and enhance GH secretion, making it a valuable tool in research focused on growth hormone dynamics and metabolic regulation.
Introduction to GHRP-2
Growth Hormone Releasing Peptide-2 (GHRP-2) is a synthetic agonist of ghrelin, a gut peptide that binds to the growth hormone secretagogue receptor. As a growth hormone secretagogue, GHRP-2 has been extensively studied for its ability to stimulate growth hormone secretion and increase food intake in animal studies. By mimicking the action of ghrelin, GHRP-2 can effectively enhance growth hormone release, making it a valuable tool in research focused on growth hormone dynamics and metabolic regulation.
Review Of GROWTH HORMONE-RELEASING PEPTIDE-2
Growth Hormone Releasing Peptide-2 (GHRP-2) represents a notable synthetic growth hormone (GH) secretagogue within laboratory settings. GHRP-2 is also known as a growth hormone releasing hexapeptide, which highlights its structure and function in stimulating growth hormone secretion.
At our facility, we maintain stringent quality standards for all research chemicals. GHRP-2 is available for procurement exclusively for research applications and laboratory investigation. It is supplied in lyophilized powder format in 5 mg containers.
WHAT IS GHRP-2: A Growth Hormone Releasing Hexapeptide
Growth Hormone Releasing Peptide-2, alternatively designated as Pralmorelin or KP-102, constitutes a novel 2nd generation synthetic hexapeptide comprising six amino acids, specifically D-Alanyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide.
GHRP-2 functions as a synthetic agonist of the hormone ghrelin, a recently identified gut peptide that demonstrates binding affinity to the growth hormone secretagogue receptor.
GHRP-2 interacts with the growth hormone secretagogue receptor, similar to the natural growth hormone releasing factor, to stimulate growth hormone secretion.
Research suggests that ghrelin exhibits two distinct properties, potentially stimulating both GH secretion and appetite regulation in experimental models.
STRUCTURE OF GHRP-2
Molecular Formula: C45H55N9O6
Molecular weight: 817.9 g/mol
CAS number: 158861-67-7
IUPAC name: (2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide
Understanding the Molecular Structure of GHRP-2 Peptide
Laboratory investigations indicate that growth hormone-releasing peptide-2, one of the gh releasing peptides, promotes growth hormone (GH) release through mechanisms involving the hypothalamus and pituitary in experimental animal models.
Research suggests that GHRP-2 may intensify natural growth hormone-releasing signals, potentially resulting in substantial growth hormone secretion in test subjects. GHRP-2 works in synergy with growth hormone releasing hormone (GHRH) to enhance growth hormone secretion.
Secondary research findings indicate it may suppress somatostatin production in laboratory specimens, a substance also referred to as growth hormone inhibiting hormone (GHIH).
Studies propose that GHRP-2 activates ghrelin, a peptide hormone produced within gastrointestinal systems of research subjects, which appears to influence not only growth hormone secretion but also plays a significant role in regulating energy balance and appetite. Ghrelin, often referred to as the “hunger hormone,” interacts with the central nervous system to signal hunger and stimulate food intake. In addition to its effects on appetite, ghrelin has been shown to have various other physiological roles, including modulation of insulin-like growth factor levels and potential impact on body composition by promoting lean muscle mass. GHRP-2, through its action on ghrelin receptors, may enhance these effects, making it a key peptide of interest in studies focused on metabolic health, obesity, and related pathophysiological conditions.
Examining GHRP-2 in Research Settings: Potential Research Findings and Laboratory Applications
Research data collected from experimental animal models suggests that GHRP-2 may demonstrate the following potential outcomes in controlled laboratory settings:
Research suggests enhanced adipose tissue reduction
Studies have shown that GHRP-2 administration can lead to a significant increase in serum GH levels, which is indicative of its potent effect on growth hormone secretion
Laboratory studies indicate possible increases in muscular tissue development
Experimental models demonstrate accelerated tissue regeneration
Research points to potential cardiovascular system improvements
Preliminary data indicates possible discomfort reduction properties
Studies suggest enhancement of skeletal structural density
Experimental observations note possible immunological response improvements
GHRP-2 has shown promise in addressing GH deficiency by significantly increasing growth hormone levels and improving growth rates in affected individuals.
GHRP-2 RESEARCH CONSIDERATIONS
Laboratory observations have documented these potential experimental variables:
Fluid accumulation in test subjects
Altered hormonal parameters including elevated cortisol and prolactin levels
Reduced energy states in experimental models
Altered glucose processing efficiency
Sensory alterations in experimental subjects
Several clinical studies have explored the effects of GHRP-2 on gh releasing, growth hormone secretion, and food intake.
SOURCES FOR GHRP-2 FOR RESEARCH PURPOSES
When conducting investigations utilizing research compounds, it is essential to acquire materials from established analytical laboratories to maintain experimental integrity and validity.
Loti Labs provides research materials with comprehensive analytical verification documentation at competitive research budget rates. Our technical support team offers detailed consultation for research applications, and we maintain favorable policies regarding material exchange when acquiring GHRP-2 compounds for laboratory investigations.
For procurement of GHRP-2 for research applications, please visit our scientific portal or communicate with our technical team through appropriate channels.
References:
Graul, Ann I.; Prous, J.R. (2006). “The Year’s New Drugs: A Historical and Research Perspective on the 41 New Products that Reached their First Markets in 2005”. Drug News & Perspectives. 19 (1): 33. ISSN 0214-0934.
Moulin, Aline; Brunel, Luc; Verdie, Pascal; Gavara, Laurent; Martinez, Jean; Fehrentz, Jean-Alain (2014). “Ghrelin Receptor Ligands: Design and Synthesis of Pseudopeptides and Peptidomimetics”. Current Chemical Biology. 7 (3): 254–270. doi:10.2174/2212796807999131128125920. ISSN 2212-7968.
J. Larry Jameson; Leslie J. De Groot (25 February 2015). Endocrinology: Adult and Pediatric: Expert Consult – Online. Elsevier Health Sciences. pp. 1366–. ISBN 978-0-323-32195-2.
Adis Editorial (2004). “Pralmorelin”. Drugs in R&D. 5 (4): 236–239. doi:10.2165/00126839-200405040-00011. PMID 15230633.
Furuta S, Shimada O, Doi N, Ukai K, Nakagawa T, Watanabe J, Imaizumi M (2004). “General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide”. Arzneimittelforschung. 54 (12): 868–80. doi:10.1055/s-0031-1297042. PMID 15646371. S2CID 28632234.
